lung fields. There were no other symptoms or signs. Pulmonary-function tests indicated that the percent vital capacity (%VC) was 87%, and that the percent forced expiratory volume in one second (FEV1.0%) was 81%. At that time, the patient was prohibited from continuing this work. A follow-up chest X-ray obtained in November showed findings similar to the findings of the previous month. A beryllium-specific lymphocyte transformation test (Be-LT) was negative (100-190%) until March 1994, but by November had clearly turned positive (927%). A chest X-ray in March 1995 showed almost the same shadows as were seen on the previous examination in October. There were no symptoms or signs. Pulmonary-function tests showed a %VC of 85% and FEV1.0% of 80%. However, since the Be-LT gave a stronger positive reaction (2,108%), the patient was suspected of having CBD. At that time, relocation of personnel from the Be workplace was carried out. After the patient experienced mild dyspnea in July 1995, betamethasone (1.5 mg) was started in August. The symptoms improved, and the dosage of betamethasone was gradually decreased.
Around August 1998, the patient's dry cough, anorexia, weight loss, and dyspnea became aggravated. On October 5, the patient visited the company-affiliated clinic. On examination, the patient had dyspnea (Hugh-Jones ) and cyanosis of the lips and nails. A chest X-ray showed linear and reticular shadows, in addition to the diffuse fine granular shadows (Fig. 2) . The patient's pulmonary function had decreased (%VC, 47%; FEV1.0%, 62%). On blood gas analysis, the PaO 2 was 50.4 torr and the PaCO 2 was 42.6 torr, indicating marked hypoxemia. The patient was admitted to the division of respiratory disease at our university hospital on October 6 for definitive diagnosis and treatment.
On admission, the patient's height was 170 cm, weight 58 kg, temperature 36.7 , and blood pressure 120/80 mmHg. His pulse was 84 per minute and regular, and his respiratory rate was 18 per minute and regular. Mild cyanosis of the fingers was noted. Heart sounds were normal; no murmurs were heard. Respiratory sounds were normal.
Laboratory findings on admission included normal white-blood-cell and red-blood-cell counts. Serological testing revealed an increase in ACE (27.4 IU/l).
Immunological testing showed increased IgG, IgM, and IgD levels, decreased T-cells (CD3) (38.8%), and a CD4/CD8 ratio of 0.51 (Table 1) .
Chest CT on October 9 showed diffuse granular shadows in both lung fields and linear shadows in the upper and middle lung lobes. Slightly enlarged lymph nodes were noted in the pretracheal and subaortic arch regions (Fig. 3) .
Bronchoscopic examination on October 13 revealed no bronchial constriction or vascular dilatation. The secretions were normal. There were no contributory findings noted in the endobronchial cavity.
Bronchoalveolar lavage fluid (BALF) was collected from the right B5a lung segment. The findings are shown in Table 2 . Bronchoalveolar lavage cells showed a noticeable increase in CD3, and a decrease in CD19. The CD4/CD8 ratio was 35%. A decrease in macrophages and an increase in lymphocytes, neutrophils, and eosinophils were observed.
Transbronchial lung biopsy specimens were bronchoscopically collected from the right B3a and B8a lung segments. As shown in Fig. 4 , multiple nodules, composed of histiocytes containing Langhans-type giant cells, had formed in the cell interstitium. In addition, a non-necrotic epithelioid granulomatosis and invasion of small lymphocytes were observed surrounding the nodules. The patient was finally diagnosed as having an acute exacerbation of CBD based on the following findings: (1) occupational history of beryllium exposure (Be fumes as BeO); (2) histopathological evidence of epithelioid cellular granulomatosis of the lung; (3) beryllium sensitization (positive Be-LT); (4) diffuse fine granular shadows on Xray films and CT scan of the chest; (5) restrictive and diffusing disorders documented on pulmonary-function tests, and hypoxemia on blood gas analysis; and (6) symptoms and signs.
During the patient's hospital stay, bronchoscopy was done on October 13. After 3 days of methylprednisolone pulse therapy, oral prednisolone 30 mg was initiated. The results of pulmonary function testing and blood gas analysis before and after corticosteroid pulse therapy are shown in Table 3 . The %VC, pulmonary diffusing capacity, and hypoxemia tended to improve. After the patient's condition improved sufficiently, the prednisolone dosage was decreased by 2.5 mg every two weeks. The patient was discharged from hospital on December 11.
Discovered in the first half of the 19th century, beryllium became an indispensable metal for the development of the nuclear and aerospace industries in the 1940s. Recently, the demand for beryllium-copper alloy has risen as a result of its use as a point of contact and a spring material for electronic machine parts. The health hazards of beryllium exposure have been reported from about 1943, with some 900 reported cases, a significant portion from the United States 3) .
In Japan, low temperature calcination and the high purity of active BeO have received much attention as being major contributing factors of CBD, and have actually been found to be involved in the occurrence of CBD in 22 of 24 previously reported Japanese cases 1) .
The first Japanese case of CBD was reported in 1964 and involved a man engaged in the chemical analysis of beryllium 4) . In the 1970s, 22 additional cases of CBD apparently involving BeO exposure were reported. Most of these CBD patients had been occupationally exposed to beryllium in the 1960s, when the safety of the workplace environment was not as well managed as today. Since then, the work environment in Be-related factories has improved remarkably. As a result, coupled with the enforcement of rules on the prevention of hazards by specific chemical substances in 1972, there has been no occurrence of new patients at the Be-related factories. Nevertheless, two cases of CBD were reported in the 5, 6) . One case involved a woman engaged in shaving beryllium-copper alloy 5) , and the other involved a man responsible for lengthening beryllium-copper alloy wire 6) . The present case involved an engineer involved in the development of production technology who was conducting examinations of equipment. This equipment was being re-introduced for the purpose of automating the disposal of sludges that occur in the process of reducing imported BeO powder in an arc furnace and in the process of making an ingot of about 2% Be-copper alloy from 4% Be-copper alloy in an arc furnace and a reducing furnace in an area where workers are generally not allowed. At these workplaces, two workers were assisting the patient as needed, but no health-related abnormalities occurred in these workers. It appears likely that the patient may have been exposed to metal beryllium fumes, which are assumed to change immediately to BeO when exposed to air, that were generated from an opening just above the furnace, rather than by the BeO powder itself. The results of the environmental measurement taken in October 1994 confirmed that the Be concentration exceeded 25 µg/m 3 transiently in the breathing zone in this workplace. Local ventilation equipment of the ring-hood type was installed in the workplace, but the local ventilation equipment sometimes failed to work during the construction work of the automation process. Furthermore, it was confirmed that wearing of a dust-proof mask became incomplete when one worker gave an instruction to the other worker during work.
Our patient's Be-LT findings were negative until March 1994, and then turned positive in November 1994. Given these findings, it can be assumed that the time during which beryllium exposure was directly involved with the occurrence of CBD was from March to November 1994, when the mechanization of the sludge processing at the reduction furnace was actually being tested.
Both a decrease in the ratio of T-lymphocytes in the peripheral blood and an increase in the ratio of T-lymphocytes to bronchoalveolar lavage cells were observed. The CD4/CD8 ratio decreased in the peripheral blood and the BALF. It is frequently reported that CBD is associated with the accumulation of T-lymphocytes in the peripheral blood, an increase in the ratio of T-lymphocytes to bronchoalveolar lavage cells, and an increase in the CD4/CD8 ratio. In our patient, although T-lymphocytes in the BALF were markedly increased, the CD4/CD8 ratio decreased. CD8 cells are suppressor/ cytotoxic cells. These findings may reflect the fact that the immune response is fully maintained and is not significantly inhibited in cases, such as ours, of early CBD 7) . Confirmation of this phenomenon must await further follow-up to examine changes in the lymphocyte subsets in BALF. With respect to humoral immunity, since hypergammaglobulinemia and elevated serum levels of IgG, IgM, and others were observed in our patient, as has also been reported elsewhere, much attention has been given to the involvement of humoral immunity, as well as cellmediated immunity, due to beryllium exposure, in the occurrence of CBD.
On the other hand, biochemical testing showed an increase in ACE, as has been seen with sarcoidosis. ACE has been shown to decrease or increase depending on the pathologic state of CBD 8) . Given this, our patient requires further follow-up.
As soon as a definite diagnosis of CBD is made, whether acute or chronic, beryllium exposure should be terminated and rest, symptomatic therapy, and occasional oxygen inhalation therapy needs to be initiated. Although no definitive therapy for CBD has been established, adrenocortical hormone agents are very effective therapy for respiratory symptoms, such as coughing and dyspnea. Such drugs are known to occasionally have a marked effect on symptoms, particularly with acute aggravations of CBD. The corticosteroid pulse therapy that was used with our patient was similar to the large doses of steroid hormone used with renal transplantation by Kounts et al. in 1969 9) . In Japan, pulse therapy was used for idiopathic interstitial pneumonia by Yoneda et al. in 1978 10) . Since then, it has been considered that this therapy is applicable mainly to cases of idiopathic interstitial pneumonia 11) . We believed that corticosteroid pulse therapy was indicated in our patient, since his CBD was aggravated relatively rapidly. However, if the medication is interrupted, even after the patient's condition stabilizes, CBD has been found to frequently relapse or become aggravated. In some reports, CBD gradually progressed or was spontaneously cured [12] [13] [14] . Clearly, our patient requires further monitoring.
